Wilson Disease
📧 Sign up to get email alerts when something new happens for Wilson Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: The Exploratory Handheld Optical Coherence Tomography Study in Wilson's Disease [NA]
The document reports completion of an exploratory handheld optical coherence tomography study in Wilson disease.
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: Natural History of Wilson Disease
A Yale-sponsored clinical study is currently recruiting to characterize the natural history of Wilson disease.
-
CLINICAL_TRIALS research · 2025-05-01Clinical Trial Update: ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders [NA]
Clinical trial update on ExAblate Transcranial MRgFUS for treatment-refractory movement disorders; the study is currently active but not rec…
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: The Clinical Study of Botulinum Toxin Type A Injection in the Treatment of Wilson Disease
A completed clinical trial evaluating botulinum toxin type A injections for Wilson disease.
-
EMA approval · 2024-12-18EMA Authorised: Wilzin (zinc) — Recordati Rare Diseases
The European Medicines Agency authorized Wilzin, a zinc-containing medicine, for Wilson disease (hepatolenticular degeneration) in the EU.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-05Clinical Trial Update: French Wilson Disease Registry
This clinical trials registry entry indicates the Wilson disease study NCT05231876 is currently recruiting, sponsored by Fondation Ophtalmol…
-
CLINICAL_TRIALS research · 2024-11-21Clinical Trial Update: Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children [NA]
A clinical trial is evaluating daily versus alternate-day plasma exchange in children with Wilson disease and acute liver failure; the study…
-
CLINICAL_TRIALS research · 2024-10-29Clinical Trial Update: An Exploratory Study to Evaluate the Tolerability and Safety of MWAV201 in Subjects With Wilson Disease [NA]
An exploratory clinical trial evaluating the tolerability and safety of MWAV201 in individuals with Wilson disease; the study is sponsored b…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease [Phase 3]
A Phase 3 trial evaluating ALXN1840 versus standard of care in pediatric Wilson disease participants was terminated, and trial results have …
-
CLINICAL_TRIALS research · 2024-06-20Clinical Trial Update: Spanish Wilson Disease Registry
A Spanish Wilson disease registry is currently recruiting participants, sponsored by Asociación Española para el Estudio del Hígado.
-
FDA approval · 2024-04-25FDA Approved: GALZIN — Supplemental Application (Eton Pharmaceuticals, Inc.)
FDA approved a supplemental application for GALZIN (zinc acetate) from Eton Pharmaceuticals, Inc. The document outlines the regulatory submi…
-
CLINICAL_TRIALS trial_result · 2024-02-09Clinical Trial Update: Gandouling in the Treatment of Wilson's Disease [Phase 4]
Phase 4 clinical trial update for Gandouling in Wilson's Disease; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants [Phase 1]
Phase 1 pharmacokinetic study of oral ALXN1840 in Japanese and non-Japanese healthy adults completed; results posted.
-
CLINICAL_TRIALS trial_result · 2023-10-27Clinical Trial Update: Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 [Phase 2]
Phase 2 results from a trial of ALXN1840 in Wilson disease report copper and molybdenum balance in participants. Results were posted on 2023…
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease [Phase 3]
A Phase 3 trial comparing ALXN1840 to standard of care in Wilson disease was terminated, and results were posted on 2023-10-10.
-
FDA approval · 2023-09-22FDA Approved: TRIENTINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for trientine hydrochloride from Rising Pharma Holdings, Inc. This action updates the regulatory…
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants [Phase 1]
Phase 1 study evaluating ALXN1840's effect on metabolism of a CYP2B6 substrate in healthy participants, completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-08-21Clinical Trial Update: Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. [Phase 1]
Phase 1 study evaluating ALXN1840's effect on metabolism of a CYP2C9 substrate in healthy participants completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 [Phase 2]
Phase 2 clinical trial results evaluating ALXN1840 for Wilson disease, including copper concentration and liver histopathologic changes; res…
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease [Phase 3]
Phase 3 trial results for trientine tetrahydrochloride in Wilson disease have been completed, with results posted in April 2023.
-
FDA approval · 2022-06-23FDA Approved: TRIENTINE HYDROCHLORIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' Trientine hydrochloride under an original generic application. The drug is indicated for Wilson disease…
-
FDA approval · 2022-04-28FDA Approved: CUVRIOR — Original Application (Orphalan SA)
FDA approves CUVRIOR (trientine tetrahydrochloride) under an original New Drug Application from Orphalan SA for Wilson disease.
-
FDA approval · 2021-10-08FDA Approved: PENICILLAMINE — Original Application (Navinta LLC)
FDA approved Navinta LLC's original application for penicillamine, making this generic available in the U.S. for approved indications such a…
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients [Phase 2]
Phase 2 trial assessing efficacy and safety of WTX101 (ALXN1840) in adults with Wilson disease has completed with results posted.
-
FDA approval · 2021-08-23FDA Approved: PENICILLAMINE — Original Application (Breckenridge Pharmaceutical, Inc.)
The FDA approved Breckenridge Pharmaceutical's penicillamine under its original application (ANDA 215409), enabling a generic version of pen…